JP2016210789A - Agent for suppressing increase of blood alcohol concentration - Google Patents
Agent for suppressing increase of blood alcohol concentration Download PDFInfo
- Publication number
- JP2016210789A JP2016210789A JP2016147095A JP2016147095A JP2016210789A JP 2016210789 A JP2016210789 A JP 2016210789A JP 2016147095 A JP2016147095 A JP 2016147095A JP 2016147095 A JP2016147095 A JP 2016147095A JP 2016210789 A JP2016210789 A JP 2016210789A
- Authority
- JP
- Japan
- Prior art keywords
- dextrin
- blood
- alcohol concentration
- blood alcohol
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 239000008280 blood Substances 0.000 title claims abstract description 47
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 229920001353 Dextrin Polymers 0.000 claims abstract description 68
- 239000004375 Dextrin Substances 0.000 claims abstract description 68
- 235000019425 dextrin Nutrition 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims description 14
- 230000035622 drinking Effects 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000008107 starch Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 239000008213 purified water Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000013334 alcoholic beverage Nutrition 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 108090000637 alpha-Amylases Proteins 0.000 description 9
- 102000004139 alpha-Amylases Human genes 0.000 description 9
- 229940024171 alpha-amylase Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 235000006408 oxalic acid Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 230000003625 amylolytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VGTALXLMFZXQSK-SORNOFNASA-N (2s,3r,4s,6ar,6br,8as,12as,14br)-2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)C2CC[C@@]3(C)[C@]4(CO)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CCC3[C@]21C VGTALXLMFZXQSK-SORNOFNASA-N 0.000 description 1
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- VGTALXLMFZXQSK-UHFFFAOYSA-N Presenegenin Natural products C1C(O)C(O)C(C)(C(O)=O)C2CCC3(C)C4(CO)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C VGTALXLMFZXQSK-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 229940105039 coconut extract Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N pantetheine Chemical compound OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- FKKZBCYPCGDQKZ-UHFFFAOYSA-N tenuifolin Natural products CC1(C)CCC2(CCC3(O)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(C)(C5CCC34C)C(=O)O)C2C1)C(=O)O FKKZBCYPCGDQKZ-UHFFFAOYSA-N 0.000 description 1
- 108010075550 termamyl Proteins 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Alcoholic Beverages (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
Abstract
Description
本発明はアルコール飲料を摂取したときの、血中アルコール濃度の急激な上昇を抑制する抑制剤及び抑制方法に関する。 The present invention relates to an inhibitor and a method for suppressing a rapid increase in blood alcohol concentration when an alcoholic beverage is ingested.
アルコールを過度に摂取した場合、急性及び慢性の中毒症状を呈することがしばしば見受けられることから、従来、酩酊の予防、酔いざまし促進、アルコール中毒の予防の目的で、特効薬を探すべく種々の検討が行われてきた。特に酩酊の予防、酔いざまし促進については古来よりの言い伝えを含め様々な物質が提案されている。
例えば、従来、果物に多く含まれる果糖やグルコース、柿の実エキス、有機酸、酢酸ナトリウム、酵母菌体、ω６系不飽和脂肪酸、塩化カルニチンおよびチクセツニンジン、エゾウコギなどが、酩酊予防や悪酔い防止剤として提案されている。
また、例えば特許文献１には、清酒の醸造により得られる酒粕の乾燥物を含有してなることを特徴とするアルコール吸収抑制組成物が開示されている。特許文献２には、カフェインを有効成分とするアルコール吸収抑制剤が開示されている。特許文献３には、オレアノール酸をサポゲニンとする配糖体、プレセネゲニンをサポゲニンとする配糖体、ヘデラゲニンをサポゲニンとする配糖体及びプロトエシゲニンをサポゲニンとする配糖体の少なくとも１種類を含有することを特徴とするアルコール吸収抑制剤が開示されている。特許文献４には、グリセロールを血中アルコール濃度上昇阻害用有効成分として含有することを特徴とする、血中アルコール濃度上昇阻害飲料が開示されている。特許文献５には、塩基性アミノ酸またはその塩を有効成分として含有する血中アルコール濃度上昇抑制用組成物が開示されている。特許文献６には、大豆蛋白を酵素分解して得られる平均分子量５００〜１５０００のペプチド混合物を有効成分とする血中のアルコール代謝改善組成物が開示されている。特許文献７には、大豆加工物を有効成分とするアルコール吸収代謝調整剤が開示されている。特許文献８には、黒糖を原料として発酵させた発酵産物を含む血中アルコール濃度を減少させるための飲食用組成物が開示されている。
しかしながら、上記従来技術は、その効果が不十分であるか、その飲料としての投与に困難が伴うなど実用化されるに至っているものは少ない。
Since excessive intake of alcohol often causes symptoms of acute and chronic poisoning, various studies have been conducted to find specific drugs for the purpose of preventing sputum, promoting sickness and preventing alcoholism. Has been done. In particular, various substances have been proposed for preventing sputum and promoting drunkness, including legends from ancient times.
For example, fructose, glucose, coconut extract, organic acid, sodium acetate, yeast cells, ω6-unsaturated fatty acids, carnitine chloride, chixetsuninjin, Ezokogi, etc. It has been proposed as an agent.
Further, for example,
However, few of the above-mentioned conventional techniques have been put into practical use because of insufficient effects or difficulty in administration as a beverage.
本発明は、より安全でより投与し易い、飲酒時の血中アルコール濃度上昇を抑制する物質を提供するものである。本発明は、飲酒時の酩酊状態を予防でき、さらに、飲酒による脂肪肝等の肝機能障害の予防にもつながる血中アルコール濃度上昇抑制剤及びその使用方法を提供しようとするものである。 The present invention provides a substance that suppresses an increase in blood alcohol concentration during drinking, which is safer and easier to administer. The present invention is intended to provide a blood alcohol concentration increase inhibitor that can prevent a drunken state at the time of drinking and also prevents liver dysfunction such as fatty liver caused by drinking and a method for using the same.
本発明者らは飲酒時の酩酊を予防する食品素材につき鋭意検討を重ねた結果、デキストリン類、とりわけ難消化性デキストリンが、飲酒後の血中アルコール濃度を顕著に抑制することを見出し、さらに研究を重ねて、本発明を完成するに至った。すなわち、本発明は、デキストリン類、特に消化性デキストリン又は難消化性デキストリンを有効成分として含有することを特徴とする、血中アルコール濃度上昇抑制剤に関する。また、本発明は、アルコール飲料摂取時に摂取アルコール量の２分の１以上のデキストリン類を摂取することによる、血中アルコール濃度の上昇抑制方法を提供する。 As a result of intensive studies on food materials for preventing wrinkles during drinking, the present inventors have found that dextrins, particularly indigestible dextrins, remarkably suppress the blood alcohol concentration after drinking. As a result, the present invention has been completed. That is, the present invention relates to a blood alcohol concentration increase inhibitor characterized by containing dextrins, particularly digestible dextrins or indigestible dextrins as active ingredients. In addition, the present invention provides a method for suppressing an increase in blood alcohol concentration by ingesting dextrins having a half or more of the ingested alcohol amount when ingesting an alcoholic beverage.
本発明によれば、アルコール飲料摂取後の急激な血中アルコール濃度の上昇を抑制することができ、安全且つ投与し易いアルコール血中濃度上昇抑制剤及びアルコール血中濃度上昇抑制方法を提供することが出来る。前記抑制剤及び抑制方法により、飲酒時の酩酊状態を予防し、さらに、中長期的には、脂肪肝等の飲酒による肝障害の予防にもつながる健康的な飲酒が可能となる。 According to the present invention, there are provided an alcohol blood concentration increase inhibitor and a method for suppressing alcohol blood concentration increase that can suppress a rapid increase in blood alcohol concentration after ingestion of an alcoholic beverage and are safe and easy to administer. I can do it. By the inhibitor and the suppression method, it is possible to prevent a drought state during drinking, and further, in the medium to long term, healthy drinking that leads to prevention of liver damage due to drinking such as fatty liver.
本明細書において「デキストリン類」とは、澱粉又は焙焼デキストリンを、酸又はアミラーゼ等の澱粉分解酵素で分解して得られる澱粉分解物、焙焼デキストリン分解物又はそれらの誘導体の総称である。「デキストリン類」には、焙焼デキストリン、消化性デキストリン、難消化性デキストリン及びそれらの水素化物が包含される。 In the present specification, “dextrins” is a general term for starch degradation products, roasted dextrin degradation products, or derivatives thereof obtained by degrading starch or roasted dextrin with an amylolytic enzyme such as acid or amylase. “Dextrins” include roasted dextrin, digestible dextrin, indigestible dextrin and hydrides thereof.
消化性デキストリンとは、澱粉を酸又はアミラーゼ等の澱粉分解酵素で分解して得られる澱粉分解物である。難消化性デキストリンとは、焙焼デキストリンを酸又はアミラーゼ等の澱粉分解酵素で分解して得られる非消化性のデキストリンである。消化性デキストリンまたは難消化性デキストリンの水素化物とは、金属触媒の存在下、加圧条件に、それらに水素ガスを接触させて接触還元したものを意味する。 Digestible dextrin is a starch degradation product obtained by degrading starch with an amylolytic enzyme such as acid or amylase. Indigestible dextrin is non-digestible dextrin obtained by decomposing roasted dextrin with an amylolytic enzyme such as acid or amylase. The hydride of digestible dextrin or indigestible dextrin means a product obtained by catalytic reduction by bringing hydrogen gas into contact with it under pressure in the presence of a metal catalyst.
デキストリン類を製造するために用いられる焙焼デキストリンとは、澱粉を、塩酸等の無機酸又はシュウ酸等の有機酸の存在下に、１２０〜２００℃に加熱して得られる乾式澱粉分解物であり、少量の非消化性成分を含むデキストリンである。
より詳細には、澱粉に鉱酸（例えば、塩酸、硝酸、硫酸）、好ましくは塩酸を、澱粉１００質量部に対して、例えば、１質量％の塩酸水溶液として３〜１０質量％添加し、加熱処理して得られる。加熱処理の前に、澱粉と鉱酸の水溶液を均一に混合するために、適当なミキサー中で撹拌、熟成（数時間）させてから、好ましくは１００〜１２０℃程度で予備乾燥して、混合物中の水分を５質量％程度まで減少させることが好ましい。加熱処理は、１２０〜２００℃、好ましくは１５０〜２００℃で１０〜１２０分、好ましくは３０分〜１２０分が適当である。加熱処理の温度は高くする方が目的生成物中の難消化性成分の含量を増加させるが、１８０℃から着色物質を生成する傾向があるので、より好ましくは１５０〜１８０℃である。
The roasted dextrin used for producing dextrins is a dry starch decomposition product obtained by heating starch to 120-200 ° C. in the presence of an inorganic acid such as hydrochloric acid or an organic acid such as oxalic acid. It is a dextrin containing a small amount of non-digestible components.
More specifically, mineral acid (for example, hydrochloric acid, nitric acid, sulfuric acid), preferably hydrochloric acid is added to starch in an amount of 3 to 10% by mass as a 1% by mass aqueous hydrochloric acid solution with respect to 100 parts by mass of starch, followed by heating. It is obtained by processing. Before the heat treatment, in order to uniformly mix the aqueous solution of starch and mineral acid, the mixture is stirred and aged in a suitable mixer (several hours), and is preferably pre-dried at about 100 to 120 ° C. It is preferable to reduce the water content to about 5% by mass. The heat treatment is performed at 120 to 200 ° C., preferably 150 to 200 ° C. for 10 to 120 minutes, preferably 30 to 120 minutes. A higher temperature for the heat treatment increases the content of indigestible components in the target product, but since it tends to form a colored substance from 180 ° C, it is more preferably 150 to 180 ° C.
消化性デキストリンまたは非消化性デキストリンの製造における澱粉又は焙焼デキストリンの酸による分解において用いられる酸は、有機酸（例えばシュウ酸、クエン酸）でも無機酸（例えば塩酸、硝酸、硫酸）でもよいが、塩酸、シュウ酸等が好ましく、更に塩酸が好ましい。
消化性デキストリンの製造には、一般的に湿式分解が用いられる。より詳細な製造方法は次のとおりである。澱粉を濃度２０〜４０％となるように水に懸濁させ、炭酸カルシウムやシュウ酸でｐＨを５．５〜６．５に調整した後、α―アミラーゼを固形分に対して０．０５〜０．３質量％添加して、加熱温度８０〜１００℃で３０〜６０分程度加水分解して澱粉を液化し、次いで０．２ＭＰa程度に加圧、又はシュウ酸等の酸を添加して酵素反応を停止させる。反応停止液を精製、濃縮、乾燥して製品とする。
The acid used in the degradation of starch or roasted dextrin with acid in the production of digestible or non-digestible dextrin may be an organic acid (eg oxalic acid, citric acid) or an inorganic acid (eg hydrochloric acid, nitric acid, sulfuric acid) Hydrochloric acid, oxalic acid and the like are preferable, and hydrochloric acid is more preferable.
For the production of digestible dextrins, wet decomposition is generally used. A more detailed manufacturing method is as follows. After suspending starch in water to a concentration of 20 to 40% and adjusting pH to 5.5 to 6.5 with calcium carbonate or oxalic acid, α-amylase is added to 0.05 to Add 0.3 mass%, hydrolyze for about 30-60 minutes at a heating temperature of 80-100 ° C to liquefy the starch, then pressurize to about 0.2 MPa or add an acid such as oxalic acid to the enzyme Stop the reaction. The reaction stop solution is purified, concentrated and dried to obtain a product.
難消化性デキストリンのより詳細な製造方法は次のとおりである。焙焼デキストリンを２０〜４５質量％程度の水溶液とし、焙焼デキストリン水溶液のｐＨを５.５〜６.５に調整し、α−アミラーゼを、例えばターマミル６０Ｌ（商品名、ノボ・ノルディスク・バイオインダストリー社製造）の場合は、焙焼デキストリンに対し、０.０５〜０.２質量％添加する。他のα−アミラーゼを使用する場合はその酵素の力価に応じて同等の量を添加すればよい。α−アミラーゼの添加後に溶液を加熱し、α−アミラーゼの作用温度である８５〜１００℃（α−アミラーゼの種類によって異なる）で３０分〜２時間加水分解する。次いで温度を１２０℃程度（α−アミラーセの失活温度）に上昇してα−アミラーゼ作用を停止する。この際、塩酸やシュウ酸やなどの酸を加えてｐＨをα−アミラーゼが失活する程度、即ちｐＨ４程度まで低下させてもよい。
上記消化性デキストリンまたは難消化性デキストリンは、ラネーニッケル等の金属触媒の存在下、８０〜１２０kg／ｃｍ2、１２０〜１４０℃の条件で水素ガスを接触させて接触還元して用いてもよい。
The more detailed manufacturing method of indigestible dextrin is as follows. The roasted dextrin is made into an aqueous solution of about 20 to 45% by mass, the pH of the roasted dextrin aqueous solution is adjusted to 5.5 to 6.5, and α-amylase is, for example, Termamyl 60L (trade name, Novo Nordisk Bio In the case of Industry), 0.05 to 0.2% by mass is added to the roasted dextrin. When other α-amylase is used, an equivalent amount may be added according to the titer of the enzyme. After the addition of α-amylase, the solution is heated and hydrolyzed at 85 to 100 ° C. (depending on the type of α-amylase), which is the action temperature of α-amylase, for 30 minutes to 2 hours. Next, the temperature is raised to about 120 ° C. (inactivation temperature of α-amylase) to stop the α-amylase action. At this time, an acid such as hydrochloric acid or oxalic acid may be added to lower the pH to such an extent that α-amylase is deactivated, that is, about pH 4.
The digestible dextrin or the hardly digestible dextrin may be used by contact reduction with hydrogen gas in the presence of a metal catalyst such as Raney nickel under the conditions of 80 to 120 kg / cm 2 and 120 to 140 ° C.
これらのデキストリン類としては、例えば市販のＴＫ−１６、パインデックス＃１、パインデックス＃２、ファイバーソル２、ファイバーソル２H（以上、松谷化学工業株式会社製）及びニュートリオース（ロケット社製）を挙げることができる。 As these dextrins, for example, commercially available TK-16, Paindex # 1, Paindex # 2, Fibersol 2, Fibersol 2H (above, manufactured by Matsutani Chemical Co., Ltd.) and Nutriose (produced by Rocket) Can be mentioned.
また、本発明におけるデキストリン類は、デキストリンに類似の構造及び機能を有する合成のデキストリン誘導体、例えばダニスコジャパン（株）から販売されているポリデキストロースであってもよい。
本明細書において「デキストリン誘導体」とは、デキストリンを化学的及び又は酵素的に加工したものであり、前記ポリデキストロースに加え、例えばデキストリンに糖転移酵素を作用させて得られる分岐デキストリン、澱粉にサイクロデキストリン生成酵素を作用させて得られるサイクロデキストリンを包含する。
The dextrins in the present invention may be synthetic dextrin derivatives having a structure and function similar to dextrin, such as polydextrose sold by Danisco Japan.
In the present specification, the “dextrin derivative” is a product obtained by chemically and enzymatically processing dextrin, and in addition to the polydextrose, for example, a branched dextrin obtained by allowing a glycosyltransferase to act on dextrin, and cyclolase on starch. The cyclodextrin obtained by making a dextrin producing enzyme act is included.
本発明の血中アルコール濃度上昇抑制剤及び抑制方法に使用する代表的なデキストリン類は、消化性デキストリン又は難消化性デキストリンであるが、効果の観点から、さらに好ましくは難消化性デキストリンである。消化性デキストリンと難消化性デキストリンを組み合わせて用いてもよい。この場合は、デキストリン類中に難消化性デキストリンを少なくとも８０質量％、より好ましくは９０質量％以上含むことが好ましい。 The typical dextrins used in the blood alcohol concentration increase inhibitor and the suppression method of the present invention are digestible dextrins or indigestible dextrins, and more preferably indigestible dextrins from the viewpoint of effects. A combination of digestible dextrin and indigestible dextrin may be used. In this case, the dextrins preferably contain at least 80% by mass of indigestible dextrin, more preferably 90% by mass or more.
これらのデキストリン類は、単独又は二種類以上を組み合わせて本発明の血中アルコール上昇抑制剤として使用することができる。本発明の血中アルコール濃度上昇抑制剤は、血中アルコール濃度上昇抑制効果を有する他の化合物、あるいは血中アルデヒド濃度を低下させる化合物と更に組み合わせて使用することができる。他の血中ルコール濃度上昇抑制効果を有する他の化合物としては、例えば、グリセロール、カルニチン、カフェイン、グリシン、マルチトール、ラクチトール等が挙げられる。また、血中アルデヒド濃度を低下させる化合物としては、エタノールアミン、パンテチン、パンテテイン、タウリン等が例示される。 These dextrins can be used alone or in combination of two or more as the blood alcohol elevation inhibitor of the present invention. The blood alcohol concentration increase inhibitor of the present invention can be used in combination with another compound having an effect of suppressing the blood alcohol concentration increase or a compound that decreases the blood aldehyde concentration. Examples of other compounds having an inhibitory effect on increase in blood alcohol concentration include glycerol, carnitine, caffeine, glycine, maltitol, lactitol, and the like. Examples of the compound that lowers the blood aldehyde concentration include ethanolamine, pantethine, pantethein, taurine and the like.
本発明の血中アルコール濃度上昇抑制剤は、アルコール飲料を摂取する前、摂取中、あるいは摂取後のいずれかの時点において摂取することにより、飲酒後の血中アルコール濃度の上昇を抑制できるが、効果の観点からアルコール飲料摂取前又は摂取中に、摂取することが好ましい。 The blood alcohol concentration increase inhibitor of the present invention can suppress an increase in blood alcohol concentration after drinking by ingesting at any time after ingesting or after ingesting an alcoholic beverage, From the viewpoint of the effect, it is preferable to ingest before or during the ingestion of the alcoholic beverage.
摂取方法は特に限定されないが、例えば水溶液、錠剤、顆粒等の形状で経口摂取する。また、アルコール飲料に添加して摂取してもよい。さらにはアルコール飲料の製造時に副原料として添加してもよい。本発明のアルコール濃度上昇抑制剤の摂取量の適量は、摂取するアルコール飲料に含まれるアルコール質量に依存する。摂取するアルコール質量に対して質量換算で２分の１以上であることが好ましく、２分の１未満では効果が弱くなる。 The ingestion method is not particularly limited, but for example, it is taken orally in the form of an aqueous solution, tablet, granule or the like. Moreover, you may ingest by adding to alcoholic beverages. Furthermore, you may add as an auxiliary | assistant raw material at the time of manufacture of alcoholic beverage. The appropriate amount of intake of the alcohol concentration increase inhibitor of the present invention depends on the alcohol mass contained in the alcohol beverage to be ingested. It is preferable that it is 1/2 or more in terms of mass relative to the mass of alcohol to be ingested, and if it is less than 1/2, the effect becomes weak.
アルコール飲料の製造時に副原料として添加する場合には、以下の方法で添加することが好ましい。
例えば、麦芽を用いるか又は用いないビール風味アルコール飲料の製造時に添加する場合は、糖化工程終了後の発酵前液に添加する。また、チューハイやハイボールの製造時に添加する場合は、原酒となる焼酎やウイスキーに、水溶液として、或いは炭酸水として添加する。
When adding as an auxiliary material at the time of manufacture of an alcoholic beverage, it is preferable to add with the following method.
For example, when adding at the time of manufacture of the beer flavor alcoholic beverage which uses or does not use malt, it adds to the pre-fermentation liquid after completion | finish of a saccharification process. Moreover, when adding at the time of manufacture of a chu-hi or a high ball, it adds to shochu and whiskey used as raw alcohol as an aqueous solution or as carbonated water.
本発明を実施例により更に詳しく説明するが、これらの実施例によって本発明が限定されるものではない。なお、特に断りのない限り、％は質量％を示す。
実施例１
精製水（Ｈ2Ｏ）、４０％デキストリン（ＴＫ−１６）水溶液又は４０％難消化性デキストリン（ファイバーソル２（ＦＳ２と略称することがある））水溶液と等量の４０％エタノール水溶液を、１６時間絶食させた７〜８週齢のＷｉｓｔａｒ系雄性ラットに、胃ゾンデを用いて経口投与した。溶液の投与量は合計で体重１ｋｇあたり６ｇとし、投与前（０分）及び投与３０分後から２４０分後まで経時的に尾静脈から採血し、和光純薬工業（株）のエタノール測定キット（Ｆ−キット）を用いて血中エタノール濃度を測定した。採取した血液は８倍量の０．３３Ｍ氷冷過塩素酸と混和し、遠心分離により得た上清を測定に用いた。
各溶液投与２４０分後までの血中エタノール濃度の推移を図１に示す。血中エタノール濃度は、投与６０分後にピークを示し、２４０分後にはほぼ消失した。ＦＳ２投与群は精製水投与群に比べてピーク濃度が有意に抑制され、投与３０分後から１２０分後までの濃度も有意に低かった。一方、ＴＫ−１６投与群の血中エタノール濃度は、精製水投与群よりも低く抑えられたが、投与６０分後までの上昇抑制は有意ではなかった。
Examples The present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples. Unless otherwise specified,% indicates mass%.
Example 1
Purified water (H 2 O), 40% dextrin (TK-16) aqueous solution or 40% indigestible dextrin (Fibersol 2 (sometimes abbreviated as FS2)) aqueous solution in an amount equal to 40% ethanol aqueous solution, 16 7-8 week old Wistar male rats fasted for an hour were orally administered using a stomach tube. The total dose of the solution was 6 g per kg body weight, and blood was collected from the tail vein over time from before administration (0 minutes) and from 30 minutes to 240 minutes after administration, and an ethanol measurement kit (Wako Pure Chemical Industries, Ltd.) F-kit) was used to measure blood ethanol concentration. The collected blood was mixed with 8 volumes of 0.33M ice-cold perchloric acid, and the supernatant obtained by centrifugation was used for measurement.
The transition of blood ethanol concentration up to 240 minutes after administration of each solution is shown in FIG. The blood ethanol concentration peaked 60 minutes after administration and almost disappeared after 240 minutes. In the FS2 administration group, the peak concentration was significantly suppressed as compared with the purified water administration group, and the concentration from 30 minutes to 120 minutes after administration was also significantly lower. On the other hand, the blood ethanol concentration in the TK-16 administration group was suppressed lower than that in the purified water administration group, but the rise suppression until 60 minutes after administration was not significant.
実施例２
精製水（Ｈ2Ｏ）、２０％難消化性デキストリン（ＦＳ２）水溶液又は４０％難消化性デキストリン（ＦＳ２）水溶液と等量の４０％エタノール水溶液を、１６時間絶食させた７〜８週齢のＷｉｓｔａｒ系雄性ラットに、胃ゾンデを用いて経口投与した。投与した各溶液の難消化性デキストリン濃度を表１に示す。
溶液の投与量は合計で体重１ｋｇあたり６ｇとし、投与前（０分）及び投与３０分後から２４０分後まで経時的に尾静脈から採血し、Ｆ−キットを用いて血中エタノール濃度を測定した。採取した血液は８倍量の０．３３Ｍ氷冷過塩素酸と混和し、遠心分離により得た上清を測定に用いた。
Example 2
7-8 weeks old fasted for 16 hours with purified water (H 2 O), 20% indigestible dextrin (FS2) aqueous solution or 40% indigestible dextrin (FS2) aqueous solution and equivalent amount of 40% ethanol aqueous solution Wistar male rats were orally administered using a stomach tube. The indigestible dextrin concentration of each administered solution is shown in Table 1.
The total dose of the solution was 6 g per kg of body weight. Blood was collected from the tail vein over time before administration (0 minutes) and 30 minutes to 240 minutes after administration, and the blood ethanol concentration was measured using the F-kit. did. The collected blood was mixed with 8 volumes of 0.33M ice-cold perchloric acid, and the supernatant obtained by centrifugation was used for measurement.
表１
各溶液投与２４０分後までの血中エタノール濃度の推移を図２に示す。血中エタノール濃度は、投与６０分後にピークを示し、２４０分後にはほぼ消失した。４０％ＦＳ２投与群は精製水投与群に比べてピーク濃度が有意に抑制され、投与３０分後から１２０分後までの血中濃度も有意に低かった。一方、２０％ＦＳ２投与群の血中エタノール濃度は、投与３０分後までは精製水投与群に比べて低い値を示し、その後は精製水投与群とほぼ同じ推移を示した。 The transition of blood ethanol concentration up to 240 minutes after administration of each solution is shown in FIG. The blood ethanol concentration peaked 60 minutes after administration and almost disappeared after 240 minutes. In the 40% FS2 administration group, the peak concentration was significantly suppressed as compared to the purified water administration group, and the blood concentration from 30 minutes to 120 minutes after administration was also significantly lower. On the other hand, the blood ethanol concentration in the 20% FS2 administration group was lower than that in the purified water administration group until 30 minutes after administration, and thereafter showed almost the same transition as in the purified water administration group.
これらの結果から、摂取エタノール量の２分の１以上の難消化性デキストリンを投与した場合には血中アルコールの上昇が抑制され、望ましい投与量は摂取エタノール量と同量以上であることがわかった。 From these results, it was found that when indigestible dextrin more than half of the amount of ingested ethanol was administered, the rise in blood alcohol was suppressed, and the desired dose was equal to or greater than the amount of ingested ethanol. It was.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016147095A JP6046297B2 (en) | 2016-07-27 | 2016-07-27 | Blood alcohol level rise inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016147095A JP6046297B2 (en) | 2016-07-27 | 2016-07-27 | Blood alcohol level rise inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274820A Division JP2013124243A (en) | 2011-12-15 | 2011-12-15 | Agent for suppressing elevation of blood alcohol concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6046297B2 JP6046297B2 (en) | 2016-12-14 |
| JP2016210789A true JP2016210789A (en) | 2016-12-15 |
Family
ID=57543968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016147095A Active JP6046297B2 (en) | 2016-07-27 | 2016-07-27 | Blood alcohol level rise inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6046297B2 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0680701A (en) * | 1991-08-28 | 1994-03-22 | Matsutani Chem Ind Ltd | Difficultly digestible dextrin |
| JPH08277221A (en) * | 1995-04-06 | 1996-10-22 | Itouen:Kk | Suppressant for alcohol absorption |
| JP2002193823A (en) * | 2000-12-22 | 2002-07-10 | Toyotama Kenko Shokuhin Kk | Medicine for preventing drunken sickness and hangover |
| JP2005021006A (en) * | 2003-06-30 | 2005-01-27 | Bc:Kk | Food and drink material, food and drink, and antidote each shortly eliminating alcohol-induced influence |
| KR20050029898A (en) * | 2003-09-24 | 2005-03-29 | 충청북도 | Functional food containing persimmon vinegar powder |
| JP2007332277A (en) * | 2006-06-15 | 2007-12-27 | Matsutani Chem Ind Ltd | Preparation method for indigestible oligosaccharide-containing composition, and food and drink |
| US20090004326A1 (en) * | 2007-06-29 | 2009-01-01 | Randy Andrews | Beverage Additive and Method of Making the Same |
-
2016
- 2016-07-27 JP JP2016147095A patent/JP6046297B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0680701A (en) * | 1991-08-28 | 1994-03-22 | Matsutani Chem Ind Ltd | Difficultly digestible dextrin |
| JPH08277221A (en) * | 1995-04-06 | 1996-10-22 | Itouen:Kk | Suppressant for alcohol absorption |
| JP2002193823A (en) * | 2000-12-22 | 2002-07-10 | Toyotama Kenko Shokuhin Kk | Medicine for preventing drunken sickness and hangover |
| JP2005021006A (en) * | 2003-06-30 | 2005-01-27 | Bc:Kk | Food and drink material, food and drink, and antidote each shortly eliminating alcohol-induced influence |
| KR20050029898A (en) * | 2003-09-24 | 2005-03-29 | 충청북도 | Functional food containing persimmon vinegar powder |
| JP2007332277A (en) * | 2006-06-15 | 2007-12-27 | Matsutani Chem Ind Ltd | Preparation method for indigestible oligosaccharide-containing composition, and food and drink |
| US20090004326A1 (en) * | 2007-06-29 | 2009-01-01 | Randy Andrews | Beverage Additive and Method of Making the Same |
Non-Patent Citations (2)
| Title |
|---|
| JPN6015037866; Ｎｕｔｒｉｔｉｏｎ Ｒｅｓｅａｒｃｈ Ｖｏｌ． １１, 1991, ｐｐ． ２１７-２２２ * |
| JPN6015037868; 月刊フードケミカル Ｖｏｌ．２６， Ｎｏ．１１, 2010, ｐｐ．７１-７３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6046297B2 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013124243A (en) | Agent for suppressing elevation of blood alcohol concentration | |
| US11298317B2 (en) | Alcoholic compositions having a lowered risk of acetaldehydemia | |
| JPWO2013080354A1 (en) | Non-fermented beer flavored beverage and method for producing the same | |
| JP2010148485A (en) | Fermented alcoholic beverage with high content of ferulic acid | |
| WO2017026226A1 (en) | Beer-like effervescent beverage | |
| JP6046297B2 (en) | Blood alcohol level rise inhibitor | |
| JP6550625B2 (en) | Sparkling beverage and method for producing the same | |
| JP6513908B2 (en) | Foaming agent | |
| JP2013133313A (en) | Therapeutic agent of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash) | |
| JP2016195551A (en) | Method for manufacturing alcoholic beverage | |
| JP6403381B2 (en) | Method for reducing the aroma of malt fermented beverages | |
| JPH07285881A (en) | Excitometabolic agent for alcohol | |
| JPH0217151B2 (en) | ||
| Mladenoska et al. | Pre-fermentative treatment of a model wine with aim to serve as a functional food with decreased alcohol content |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6046297 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |